Analysis and interpretation of Iron studies and Vitamin C levels in paediatric patients with chronic renal failure by Lutz, Tracey Leigh
Analysis and Interpretation of Iron studies and Vitamin C levels in Paediatric patients with 
chronic renal failure.  
Tracey Leigh Lutz
A research report submitted to the Faculty of Health Sciences, University of the 
Witwatersrand, Johannesburg, in partial fulfilment of the requirements for the degree of 
Master of Medicine in the branch of Paediatrics.
Johannesburg 2009
ii
DECLARATION
I, Tracey Leigh Lutz, declare that this research report is my own work.  It is being submitted 
for the degree of Master of Medicine in the branch of Paediatrics in the University of the 
Witwatersrand, Johannesburg.  It has not been submitted before for any degree or 
examination at this or any other University
27th October 2009
iii
DEDICATION
To Brett, 
For his ongoing support
And encouragement
iv
ABSTRACT
This prospective observational study analysed iron studies and vitamin C levels in patients 
with chronic kidney disease attending Johannesburg Hospital Paediatric Nephrology Clinic.  
The rationale behind this study was to determine the extent of iron deficiency among patients 
in chronic renal failure.  Vitamin C deficiency is common among dialysis patients, it is easy 
to test for and easy to prevent.  This study may assist in guiding future management with 
regards to vitamin C supplementation in patients with chronic renal insufficiency on dialysis.
The study contained 45 patients of which 27 (60 %) were male and 18 (40 %) were female. 
The ages of the children varied from 2 years 1 month to 19 years and 7 months. The study 
included patients from all ethnic groups; 9 were Caucasian, 33 African, 2 Indian and 1 
Coloured.  Two male patients did not have Vitamin C levels analyzed.   
The patients were divided into 3 distinct groups; firstly those patients on haemodialysis (12 
patients), those on peritoneal dialysis (22 patients) and those not yet dialysed (11 patients).  
In all patients who were not yet on dialysis the GFR ranged between 18.1 and 45 
ml/min/1.73m2.
There were no statistically significant differences between the three groups when the results 
of the iron studies were analysed.  However, despite iron treatment 26.6 % of patients were 
iron deficient as indicated by their transferrin saturation which was less than 20 %.
Vitamin C levels were also analysed in this study.  Forty one percent of children in chronic 
renal failure were vitamin C deficient.  There was no statistically significant variability 
vamong the three groups.  Two patients (4.6%) were noted to be Vitamin C toxic.  One of 
these patients was haemodialysed; the other was not yet on dialysis.
Vitamin C deficiency in chronic renal insufficient patients on dialysis is easily correctable 
when identified.  Vitamin C in specific well documented doses is safe to administer to this 
group of patients.  It will also enhance the absorption of iron and thereby have an indirect 
effect on anaemia.
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1CHAPTER 1
INTRODUCTION
Anaemia and its association with kidney disease was first described in 1836 by 
Richard Bright.  The nature of the anaemia associated with renal disease was initially 
poorly understood (1), but with time and extensive research it has been shown that the 
aetiology of the anaemia in chronic kidney disease is multifactorial. Anaemia is an 
independent risk factor for early death in patients with chronic kidney disease.
Firstly, there is inadequate production of erythropoietin by the failing kidney.  This is 
singularly the most important reason for the anaemia. Other factors which contribute 
to the anaemia include; inhibition of erythropoeisis by uraemic toxins, excessive 
blood loss in haemodialysis circuits and increased osmolality which results in reduced 
red cell survival thereby aggravating the anaemia (2). Certain nutritional deficiencies 
are also associated with chronic kidney disease.  These include Vitamin C (ascorbic 
acid), iron and folate deficiencies.    Intoxications with substances that impair red 
blood cell development (aluminium and lead) and substances that contribute to 
haemolysis (copper) can also contribute to the anaemia of end stage renal disease (3).
The anaemia associated with chronic renal failure is usually of a progressive nature 
with pre-dialysis patients being less severely affected than those on dialysis (4). This 
suggests a linear relationship between Glomerular Filtration rate and severity of 
anaemia, the lower the GFR the less erythropoietin is produced by the failing kidney.
Anaemia is usually more common in children with chronic kidney disease than in 
adults; however, most research in this field use adult subjects. It also seems to be 
2more severe, consequently demanding more frequent blood transfusions.  The adverse 
effects of these transfusions include increased risk of viral infections (HIV, Hepatitis), 
blood borne diseases, and enhanced sensitisation to histocompatibility antigens,
thereby decreasing the success of future renal transplantation as well as iron overload 
(5). 
Anaemia has been closely linked with poor concentration, impaired physical 
capabilities (exercise intolerance), cardiovascular complications (left ventricular 
hypertrophy being the most common recorded cardiovascular abnormality), anorexia 
as well as increased mortality (6). Several studies have documented that a 
haemoglobin level of 10g/dl or less is associated with a high risk of death when 
compared with levels of more than 10g/dl (7). Correction of the anaemia has benefits 
in improving concentration, reducing left ventricular mass index, improving fatigue 
and depression as well as stimulating an improved appetite.
K/DOQI guidelines have suggested maintaining haemoglobin levels between 11g/dl 
and 12g/dl and a haematocrit above 33%.  According to these guidelines the 
monitoring of haemoglobin is preferred to haematocrit in the identification and 
management of anaemia. Haemoglobin measurement is more accurate if a time 
interval is present between collection and laboratory analysis. Hyperglycaemia also 
adversely affects the MCV (elevating it) which results in an invalid haematocrit 
reading. The laboratory variability in the measurement of haematocrit is greater than 
for haemoglobin. Maintaining a normal haemoglobin level is not always easily 
achievable. Anaemia (as mentioned above) and polycythaemia are both associated 
with complications.  Polycythaemia has been associated with an increased incidence 
3of thrombosis (including access thrombosis in patients on haemodialysis) and 
hypertension. Hypertension is a well documented complication of erythropoietin 
supplementation (8). Erythropoeitin stimulating agents have an increased thrombotic 
risk through increased inflammation and antifibrinolytic activity (9).
In newborn babies, the liver is the primary site of erythropoietin production.  Shortly 
after birth the kidneys take over this role.  Erythropoetin is primarily produced by the 
cells of the peritubular capillary endothelium of the kidney.  It is a 165 amino acid 
glycoprotein (62 % protein and 38 % carbohydrate); it is responsible for the 
regulation of red blood cell production.  Erythropoeitin induces erythropoeisis by 
stimulating the division and differentiation of committed erythroid progenitor cells. 
This accelerated erythropoeisis creates a need for additional iron (10). If available 
iron reserves are inadequate, optimal therapeutic response to erythropoietin is 
threatened by iron deficiency (11). The reticulocytes which are released from the bone 
marrow mature into red blood cells.
Erythropoietin should be supplemented subcutaneously or intravenously to all patients 
with anaemia and chronic renal failure (12). Correction of the anaemia with 
erythropoietin increases oxygen delivery to the tissues and thus reduces hypoxia (13).
Supplementation of erythropoietin into the peritoneal fluid is also effective, as it is 
absorbed in significant amounts. The one problem with intraperitoneal administration 
of erythropoietin is that the dose required is significantly higher which has a negative 
impact on cost. Comparative studies on the various routes of administration and their 
effect have not been studied in children. However, we do know that intravenous 
erythropoietin is well tolerated.  Intravenous erythropoietin is administered after a 
4dialysis session and therefore compliance is assured. Subcutaneous administration of 
erythropoietin is painful and this may affect compliance. Recommended guidelines 
suggest starting at a dose of around 50-150 U/kg/week in two or three doses. It is 
well known that younger children need relatively more erythropoietin than older ones 
(14). If there is an inadequate response (haemoglobin should increase at one
g/dl/month) the dose should be increased in stepwise increments of 50 U/kg/week. 
Patients can either respond to erythropoietin, fail to respond to it or develop a pure red 
cell aplasia.  A pure red cell aplasia is extremely rare and is due to the development of 
neutralizing antierythropoeitin antibodies.  
There are various types of erythropoietin available, erythropoietin alpha (eprex), 
erythropoietin beta (recormon) and erythropoeitin delta.  Darbopoeitin alpha has a 
longer half life and has not been found to cause a pure red cell aplasia; it is more cost 
effective due to its longer half-life (15). It is good for the stable control of anaemia in 
haemodialysis patients (16).  A new class of third generation erythropoeitic-
stimulating agents have become available; these are continuous erythropoietin 
receptor activators (CERA). Micera is similar to previous synthetic erythropoietin 
drugs, except that it is connected to a chemical called polyethylene glycol which 
makes it last longer in the body.  It has the longest half-life of all FDA-approved 
erythropoeisis stimulating agents.  This has two significant advantages; firstly, lower 
dosing which reduces cost and secondly, less frequent injections for patients which 
will impact positively on compliance.   This drug is currently available and registered 
for use in different parts of the world. Recombinant erythropoietin is 
immunologically indistinguishable from the native hormone; it would therefore not be 
expected to promote an immune response (12).
5There are a number of reasons why patients may develop resistance or fail to respond 
to erythropoietin and they include:  the development of an infection, antibodies to 
erythropoeitin (as mentioned above), vitamin C deficiency, malnutrition
(Protein/Energy Wasting), hyperparathyroidism, haemolytic disorders, vitamin B 12 
and folate deficiencies and drug ingestion (Angiotensin-Converting Enzyme 
Inhibitors) (17). The exact mechanism of how ACE inhibitors impair production of 
erythropoeitin is not clear; however, they are thought to alter tissue oxygenation and 
affect erythropoeitin production directly through angiotensin II (3). The most 
important reason for patients to fail to respond to erythropoietin is iron deficiency
(18). This can be in the form of true iron deficiency or functional iron deficiency (2).
Iron is an essential element required for growth and survival and plays a role in 
oxygen transport and various enzyme-catalyzed reactions.  Excessive free iron can be 
dangerous due to its contribution to free radical production.  
Iron supplementation forms an integral part of the management of anaemia associated 
with chronic kidney disease (19). Intravenous replacement and maintenance iron are 
frequently required in haemodialysis patients (20). Low serum iron has been 
associated with a poor clinical outcome, including significantly greater rates of 
mortality and hospitalisation (21). Indications are that the prevalence of iron 
deficiency in paediatric patients is approximately 25 % which is comparable with that 
in adults (18). The K/DOQI guidelines (22) suggest supplementing iron if the ferritin 
is less than 100ng/ml and the TSAT (percent transferrin saturation) falls below 20% 
in pre-dialysis or peritoneal dialysis patients.  In the haemodialysis group absolute 
iron deficiency is defined as a TSAT of less than 20% and a ferritin of less than 
6200ng/ml. The TSAT is calculated by multiplying serum iron by 100 and dividing it 
by the total iron binding capacity. 
The Reticulocyte Haemoglobin is also a very effective means of monitoring iron 
status (23); the reticulocyte haemoglobin content reflects the amount of iron available 
for haemoglobin production in the bone marrow. Reticulocyte haemoglobin is an 
accurate and direct measure of the effective iron supply for erythropoesis as it focuses 
on new red cells just released from the bone marrow. It is not fully understood or 
investigated whether reticulocyte haemoglobin is influenced by inflammation (24).
The testing for this form of haemoglobin is not readily available in all laboratories
(25) and as such, it has not been used in this study. 
Ferritin is often used as a marker for iron stores. The main concerns with using ferritin 
are that:
 Firstly, uraemia stimulates a chronic inflammatory response which can elevate 
ferritin despite inadequate iron stores (26).
 Secondly, in patients who have had multiple blood transfusions hepatic iron 
stores do not correlate with ferritin levels or serum transferrin.
 Finally, ferritin is an acute phase reactant and can be elevated in response to 
an infection or an inflammatory process.
Ferritin levels may be normal in patients with a functional iron deficiency; however,
they are unable to mobilise iron from these stores rapidly enough to satisfy the 
demands of the bone marrow (27).
7Hepcidin has recently been recognised as a hormone essential to the negative 
regulation of iron; it also has antimicrobial properties. It is a small peptide produced 
by the liver as pro-hepcidin; it then undergoes proteolytic cleavage to form hepcidin.  
Hepcidin acts as an essential iron-regulatory hormone; its production is regulated by 
anaemia/hypoxia, iron status and inflammation. 
When iron is absorbed in the duodenum, ferric iron is reduced to ferrous iron by 
cytochromes.  The proximal duodenal environment allows transport of this ferrous 
iron into the enterocyte.  This iron is then lost in the faeces or transferred to the 
circulation to bind transferrin.  Excess circulating iron is stored, mainly in 
hepatocytes.  This occurs by binding to ferritin. Hepcidin can block iron absorption by 
the duodenum, iron release from the liver (storage iron) and interrupt the macrophage 
recycling of iron between red cells and the reticuloendothelial system (28).   
In iron overload, hepcidin expression is increased which decreases the absorption of 
intestinal iron.  In iron deficiency the opposite occurs.  In anaemia/hypoxia hepcidin 
expression is decreased which enhances the absorption of iron (28).  In anemia of 
chronic disease or associated with chronic inflammation, hepcidin is increased which 
interferes with the absorption of iron.  This can result in a real iron deficiency if 
ongoing.  Hepcidin also decreases iron availability by increasing sequestration by the 
reticulo-endothelial system (29).
Serum hepcidin can be measured using an ELISA (Enzyme Linked Immunosorbent 
Assay).  This was developed and validated by Ganz et al (30). In healthy volunteers, 
serum hepcidin concentrations correlated with its urinary levels and with serum 
8ferritin.  Hepcidin was low or undetectable in patients with iron deficiency anaemia 
and increased in cases of inflammation.  Pro-hepcidin can also be measured using an 
ELISA; most clinical studies are based on these levels.  Pro-hepcidin appears to be a 
reliable indicator of hepcidin production.
A study by Tsuchihashi et al (31) found no difference in serum pro-hepcidin levels 
between haemodialysis patients and healthy volunteers.  Kulaksiz et al (32) found 
pro-hepcidin levels to be 30% lower in healthy volunteers than in patients on 
haemodialysis without anaemia.  Although various studies have not had the same 
result outcomes what is clear is that pro-hepcidin levels are increased in 
haemodialysis patients who are anaemic (Hb <11g/dl).  Other confounding factors in 
using hepcidin as a marker for iron status in haemodialysis patients are that 
intravenous iron and supplemented erythropoietin all influence hepcidin expression.
Iron can be given in two different forms; orally or intravenously.  There are three
different types of intravenous iron:  iron dextran, sodium ferric gluconate and iron 
sucrose (33). Supplementation of iron is not completely benign and has been
associated with anaphylaxis.  Anaphylactic reactions to intravenous iron vary from 
mild urticaria and other rashes to dyspnoea, hypotension, shock and death.  Iron 
dextran seems to have the highest incidence of anaphylaxis and death. The rationale 
behind this is that the high molecular weight dextran moiety shares carbohydrate 
antigens with gastrointestinal organisms. Delayed adverse events included 
arthralgias, myalgias, fever and headache. There is also potentially an increase in 
infection associated with the supplementation of iron (34). Iron acts as a growth 
factor for bacteria; it inhibits neutrophil function (35). Iron contributes to endothelial 
9damage and inflammation when in its free circulating form (hydroxyl). Iron also 
causes renal tubular damage, with limited data regarding severity (36).
Iron requirements are increased in patients with chronic kidney disease due to 
erythropoietin facilitated iron utilisation and iron sequestration secondary to ongoing 
chronic inflammation (37). Chronic kidney disease patients have also been noted to 
have high interleukin 6 levels which results in the modification of iron metabolism. 
In the absence of erythropoietin, iron accumulates and is redistributed to the reticulo-
endothelial system and non haematopoietic tissues.  Iron is principally accumulated in 
hepatocytes and Kupfer cells when erythropoiesis is depressed (38). Iron deficiency is 
the single most important cause for resistance to erythropoietin. For optimal response 
to erythropoeitin iron needs to be maintained within the normal range (2).
Studies done have revealed that intravenous maintenance iron in haemodialysis 
patients has allowed for the reduction in dosage of erythropoietin to maintain blood 
haemoglobin levels within the normal range.  Regular maintenance iron has a lower 
incidence of iron overload than intermittent iron boluses (37).
In haemodialysis patients intravenous use of iron has resulted in improved results 
when compared with the oral administration of iron (27). Two possible reasons for 
this are; firstly, poor compliance with the oral form and secondly, impaired intestinal 
absorption of iron.  These studies are adult based and paediatric data is limited. We 
do, however, know that certain substances enhance iron absorption i.e. Vitamin C 
while others inhibit it i.e. tannins in tea and coffee, cereals as well as dairy products.
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Oral iron should be administered without food or medication; a dose of 200mg daily 
is recommended.  The oral paediatric dose is 2-3mg/kg/day (22). 
Fishbane (34) reviewed iron replacement in non-dialysis patients with established 
kidney failure.  Most studies revealed only a modest superior efficacy of intravenous 
iron therapy when compared to oral iron.  Achieving vascular access was 
inconvenient in the out-patient setting.  Also, intravenous iron causes a transient surge 
in oxidative stress which has implications on vascular access in the future.  Further 
studies need to be done to determine the best method of administration in this group 
of patients.
Supplementation of iron to patients with chronic kidney disease has allowed for 
reduced dosages of erythropoietin – this has two identifiable benefits; firstly cost 
reduction and secondly improved safety (38). A well documented complication of 
erythropoietin is hypertension.  The erythropoietin affects endothelial and vascular 
smooth muscle thereby causing hypertension.  The hypertension related to 
erythropoietin can be improved by reducing the dosage of the drug and by changing 
its route of administration from intravenous to subcutaneous. Blood pressure 
monitoring is essential as most paediatric patients have hypertension as a result of 
their underlying renal pathology, which is further exacerbated by the use of certain 
drugs.
Very little information is available to determine the upper limit of safety of ferritin 
levels in patients on intravenous iron supplementation.  We know that iron 
accumulates in the heart, liver and pancreas (haemosiderosis) and can be hazardous.  
11
However, it has been noticed that in dialysis patients most iron accumulates in the 
reticulo-endothelial cells and very little parenchymal damage occurs.  Iron overload 
has also been associated with an increased risk of infection (22). Adult studies have 
not recommended routine iron administration when the ferritin level is above 
500ng/ml. Iron has the potential to accelerate kidney damage in patients with chronic 
kidney disease not on dialysis therapy (39).
Vitamin C or ascorbic acid is an essential nutrient that is required for the formation of 
collagen, normal immune function and for the generation of corticosteroids and 
catecholamines.  The most common clinical effects of ascorbic acid deficiency are 
gingivitis, soft tissue bleeding, fatigue and possible alterations in immune function.   
These symptoms are fairly non-specific and may be attributed to many different 
causes.
Recent research into Vitamin C levels in patients with chronic renal failure on 
haemodialysis has revealed that Vitamin C levels have been found to be subnormal in 
a significant number of patients.  The two reasons for this are poor dietary intake as 
well as intra-dialysis loss of the vitamin.  The intra-dialysis loss of the vitamin is 
enhanced due to its low molecular weight and its low or absent albumin-binding (40).  
Ascorbic acid stores depend on a number of factors; such as dietary intake, 
intracellular distribution, rate of utilization as a free radical scavenger and cofactor in 
the dihydroxygenase reactions as well as the rate of regeneration from 
monodehydroascorbate radical and dehydroascorbate. Vitamin C supplementation 
has been recommended in patients on long term haemodialysis therapy due to its 
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involvement in certain metabolic pathways and for its role as an antioxidant (41). The 
therapeutic window is however fairly narrow.
Removal of ascorbate by peritoneal dialysis is proportional to the peritoneal creatinine 
clearance.  In peritoneal dialysis patients, low ascorbate levels have been associated 
with low serum albumin. In one study, there were similar levels in the patients on 
CAPD (Continuous Ambulatory Peritoneal Dialysis) and CCPD (Continuous Cycling 
Peritoneal Dialysis) (42).
Vitamin C, being a water-soluble vitamin is excreted by the kidney.  If large doses are 
given to patients with normal renal function the kidney will simply increase the 
amount excreted through glomerular filtration and active tubular secretion.  However, 
in patients with renal failure this is not possible and it will then accumulate and 
deposit as oxalate crystals (41). The clinical significance of super saturation in the 
blood is poorly understood, however we know that tissue oxalate crystal deposition 
can only occur in a supersaturated state. Oxalate forms as a metabolite from the 
breakdown of vitamin C.   These oxalate crystals deposit in the renal tubules (calculi) 
as well as in parenchymal tissues.  A dose of 120mg of Vitamin C is unlikely to cause 
oxalosis but sufficient to prevent a deficiency. Administration of larger doses of 
ascorbic acid is associated with induction of acute free radical generation (43).
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CHAPTER 2
MATERIALS AND METHODS
2.1 Study Sample
2.1.1 Geographic and age details
This prospective observational study was carried out in the Department of Paediatric 
Nephrology at Johannesburg General Hospital from October until December 2005.  
This Study was approved by the Human Medical Research Ethics Committee of the 
University of the Witwatersrand, Johannesburg.
Forty-five patients (18 females and 27 males) were entered into the study.  The age of 
the patients included in the study varied from 2 years to 19 years 7 months (mean age 
was 12 years). The subjects were from diverse racial and ethnic groups.  There were 
9 white children, 33 black children, 1 coloured child and 2 children of Indian
ethnicity.   
The inclusion criteria consisted of all the patients who had chronic renal disease that 
gave consent or assent for the study. All patients 14 years and above gave their own 
informed consent (assent) to participate in the study; parental consent was obtained 
for patients under the age of 14 years. All patients, enrolled in the study, and their 
parents had a good understanding of English and as such it was not necessary to work 
through an interpreter. There were essentially three groups of patients:  those on 
haemodialysis (12 patients), those on continuous ambulatory peritoneal dialysis (22
patients) and those not yet dialysed (11 patients) but in established renal failure with 
all the participants having a calculated Glomerular Filtration Rate (GFR) under 
40ml/min/1.73m2 surface area (22). The aetiology of the renal failure was diverse:  
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 Alport’s Syndrome – one case
 Primary Hyperoxaluria – five cases
 Congenital Nephrotic Syndrome – four cases
 Hypoplastic kidneys – two cases
 Dysplastic kidneys – seven cases, two of which had single kidneys
 Posterior urethral valves – five cases one of which was associated with 
prune belly syndrome
 Focal segmental glomerulosclerosis - four cases
 Rapidly progressive glomerulosclerosis – one case
 Reflux nephropathies of varying grades – two cases
 VATER association with a neuropathic bladder – one case
 Autosomal recessive polycystic kidney disease – four cases
 Haemolytic uraemic syndrome – two cases
 Unknown aetiology of the renal failure – seven cases
2.1.2 Sampling method
Early morning random blood samples were taken on all patients enrolled in the study 
over a period of 6 weeks.  These specimens were taken at the time of regular 
outpatient clinic follow-up appointments.  In the patients on haemodialysis blood 
specimens were taken at the start of a three hour dialysis session.  The blood
specimens were all sent to the same laboratory for analysis of a full blood count, a 
urea and a creatinine, a c-reactive protein and iron studies.  A further six millilitres of 
blood was sent for Vitamin C analysis.  The Vitamin C was measured using the White 
Cell Vitamin C Assay method (see appendix). Only 43 out of the 45 patients enrolled 
in the study had vitamin C levels performed.
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2.1.3 Statistical Methods
2.1.3.1 Fischer’s Test
The conventional Fischer’s exact test was used to determine non random associations 
between the categorical variables. This test compared iron levels, transferrin levels 
and vitamin C levels in patients on haemodialysis, peritoneal dialysis and a group of 
patients not yet dialysed. A result of < 0.05 was considered statistically significant. 
The Fischer’s exact test was selected in favour of the chi square test due to the small 
sample size.  
2.1.3.2 Box and Whisker Plot
A Box and Whisker plot has been used to display the statistical data.  This plot easily 
identifies the mean, the spread and the overall range of distribution of iron levels, 
transferrin and vitamin C in the three groups (haemodialysis, peritoneal dialysis and 
the group not yet dialysed).
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2.2 Statistical Analysis
2.2.1.1. Iron levels
Group Normal Abnormal Total
Peritoneal Dialysis 18 patients
81.82%
Range: 11.8 – 27.2
Mean: 16.12umol/l
4 patients
18.18%
Range: 5.4 – 9.9
Mean: 7.93umol/l
22 patients
100.00%
Range: 5.4 – 27.2
Mean: 14.6umol/l
Haemodialysis 8 patients
66.67 %
Range: 10 – 28.9
Mean:  15.9umol/l
4 patients
33.33 %
Range:  2.3 – 35.7
Mean: 19umol/l
12 patients
100.00 %
Range:  2.3 – 35.7
Mean: 16.9umol/l
Non- Dialysis 8 patients
72.73 %
Range:  10 – 21.4
Mean: 15.76umol/l
3 patients
27.27 %
Range:  3.8 – 5.2
Mean: 4.57umol/l
11 patients
100.00 %
Range:  3.8 – 21.4
Mean: 12.7umol/l
Total 34 patients
75.56 %
Range:  10 – 28.9
Mean: 15.99umol/l
11 patients
24.44 %
Range:  2.3 – 35.7
Mean: 11umol/l
45 patients
100.00 %
Range:  2.3 – 35.7
Mean:  14.77umol/l
Fischer’s exact test – p value = 0.605
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2.2.1.2. Box Whisker Plot of Iron levels 
HD:  Group of Patients on Haemodialysis
PD:  Group of Patients on Peritoneal Dialysis
ND:  Group of Patients not yet dialysed
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2.2.2.1. Transferrin Saturation
Group Normal Abnormal Total
Peritoneal Dialysis 16
72.73 %
Range: 22 – 50%
Mean: 34.25%
6
27.27 %
Range: 11 – 54%
Mean: 22.67%
22
100.00 %
Range: 11 – 54 %
Mean: 31.09%
Haemodialysis 4
33.33 %
Range: 27 – 42%
Mean: 31.5 %
8
66.67 %
Range: 8 – 95 %
Mean: 57.13%
12
100.00 %
Range: 8 – 95 %
Mean: 48.58%
Non dialysis 5
45.45 %
Range: 22 – 30%
Mean: 26.8%
6
54.55 %
Range:  7 – 61%
Mean: 22.17%
11
100.00 %
Range:  7 – 61%
Mean: 24.27%
Total 25
55.56 %
Range: 22 – 50 %
Mean: 32.3%
20
44.44 %
Range:  7 – 95%
Mean:  36.3%
45
100.00%
Range: 7 -95%
Mean:  34.08%
Fischer’s exact test – p value = 0.064
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2.2.2.2. Box Whisker Plot of Transferrin Saturation Levels
HD:  Group of Patients on Haemodialysis
PD:  Group of Patients on Peritoneal Dialysis
ND:  Group of Patients not yet dialysed
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2.2.3.1. Vitamin C Levels
Group Normal Abnormal Total
Peritoneal Dialysis 13
59.09%
Range: 20.3 –
39.6umol
Mean: 26.97umol
9
40.91%
Range: 5.7 –
45.2umol
Mean: 17.04umol
22
100.00%
Range: 5.7 –
45.2umol
Mean: 22.9umol
Haemodialysis 7
58.33%
Range: 21.7 –
38.9umol
Mean: 27.3umol
5
41.67%
Range: 6.3 –
19.2umol
Mean: 13.14umol
12
100.00%
Range: 6.3 –
38.9umol
Mean: 21.4umol
Non-dialysis 3
33.33%
Range: 21.1 –
28.3umol
Mean: 23.5umol
6
66.67%
Range: 4 –
71.6umol
Mean: 21.06umol
9
100.00%
Range: 4 –
71.6umol
Mean: 21.8umol
Total 23
53.49%
Range: 20.3 –
39.6umol
Mean: 26.6umol
20
46.5%
Range: 4 –
71.6umol
Mean: 17.26umol
43
100.00%
Range: 4 –
71.6umol
Mean: 22.3umol
Fischer’s exact test – p value = 0.43
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2.2.3.2.  Box Whisker Plot of Vitamin C Levels 
HD:  Group of Patients on Haemodialysis
PD:  Group of Patients on Peritoneal Dialysis
ND:  Group of Patients not yet dialysed
umol
HD PD ND
0
8
16
24
32
40
48
56
64
72
Maximum
Minimum
75%
25%
Median
Outliers
Extremes
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CHAPTER 3
RESULTS
Analyses of Vitamin C and iron levels were done comparing the three different 
groups:  Patients on haemodialysis, peritoneal dialysis and those not yet dialysed but 
in well established renal failure.
3.1 Iron, Vitamin C and Haemoglobin Results
Study 
No.
Patient 
Age
Type of
Dialysis
Iron levels
(10-30umol/l)
Vitamin C level
(20-40umol/l)
Haemoglobin
1 15y5m PD 12.9umol/l 15.1umol/l 13.2mmol/l
2 12y2m PD 11.8umol/l 25.8umol/l 5.3mmol/l
3 16y5m PD 9.9umol/l 21umol/l 8.1mmol/l
4 14y1m PD 16.8umol/l 21.4umol/l 12.4mmol/l
5 12y 6m HD 19.7umol/l 21.7umol/l 7.8mmol/l
6 17y1m PD 10.7umol/l 13.2umol/l 6.5mmol/l
7 16y7m HD 11.2umol/l 26.6umol/l 11.3mmol/l
8 19y7m HD 10umol/l 26.4umol/l 5.7mmol/l
9 17y11m HD 13umol/l 23.4umol/l 7.9mmol/l
10 14y11m PD 12umol/l 17umol/l 8mmol/l
11 8y8m PD 21.3umol/l 29.4umol/l 6.2mmol/l
12 13y5m PD 9.8umol/l 12umol/l 10.5mmol/l
13 15y8m PD 11.8umol/l 12.3umol/l 12.1mmol/l
14 11y2m PD 21.1umol/l 32umol/l 9.1mmol/l
15 2y1m PD 27.2umol/l 45.2umol/l 9.9mmol/l
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16 15y8m HD 28.9umol/l 19.2umol/l 10.8mmol/l
17 13y1m HD 12.2umol/l 13.3umol/l 7.9mmol/l
18 5y6m HD 35.7umol/l 38.9umol/l 11.4mmol/l
19 14y4m HD 32.7umol/l 6.3umol/l 9.4mmol/l
20 10y11m HD 2.3umol/l 9.5umol/l 6.7mmol/l
21 3y1m ND 18.5umol/l 21.1umol/l 11.8mmol/l
22 13y2m PD 14.2umol/l 29.1umol/l 7.3mmol/l
23 12y4m PD 15.6umol/l 22.6umol/l 7.6mmol/l
24 13y11m PD 19.7umol/l 33.9umol/l 7.7mmol/l
25 15y ND 19.9umol/l 28.3umol/l 10.3mmol/l
26 7y5m PD 11.7umol/l 27.1umol/l 10.7mmol/l
27 12y3m PD 18.6umol/l 25.8umol/l 8.9mmo/l
28 13y7m PD 6.6umol/l 22.6umol/l 10.7mmol/l
29 14y9m ND 12.1umol/l 15.8umol/l 12.0mmol/l
30 12y3m ND 4.7umol/l 4umol/l 10.3mmol/l
31 15y4m ND 3.8umol/l 14.1umol/l 10.3mmol/l
32 17y1m PD 5.4umol/l 5.7umol/l 11.3mmol/l
33 18y7m HD 18.6umol/l 24.2umol/l 11.4mmol/l
34 13y8m HD 13.6umol/l 17.4umol/l 6.1mmol/l
35 8y5m ND 10.5umol/l 21.2umol/l 11.1mmol/l
36 9y8m PD 14.3umol/l 20.3umol/l 16.3mmol/l
37 6y6m PD 17umol/l 39.6umol/l 13.4mmol/l
38 13y5m ND 21.4umol/l 71.6umol/l 8.7mmol/l
39 14y9m ND 17.6umol/l Not analyzed 14.4mmol/l
24
40 10y4m ND 5.2umol/l 13.1umol/l 10.6mmol/l
41 9y1m HD 5.3umol/l 30.1umol/l 6.6mmol/l
42 15y11 ND 16.1umol/l 7.5umol/l 14.6mmol/l
43 15y3m PD 14.9umol/l 17.8umol/l 9.5mmol/l
44 11y4m PD 18.7umol/l 15.1umol/l 7.6mmol/l
45 17y5m ND 10umol/l Not analyzed 12.7mmol/l
HD:  Group of Patients on Haemodialysis
PD:  Group of Patients on Peritoneal Dialysis
ND:  Group of Patients not yet dialysed
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3.2 Iron toxicity and deficiency
Deficient Toxic
Peritoneal Dialysis 4 (22) (18.2%)
Range: 5.4 - 9.9umol/l
Mean: 7.93umol/l
0 (22)           (0%)
Haemodialysis 2 (12)          (16.7%)
Range: 2.3 – 5.3umol/l
Mean: 3.8umol/l
2 (12)          (16.7%)
Range:  32.7 – 35.7
Mean: 34.2umol/l
Non-dialysis 3 (11)         (27.3%)
Range: 3.8 – 5.2umol/l
Mean: 4.57umol/l
0 (11)           (0%)
Total 9 (45)          (20%)
Range: 2.3 -9.9umol/l
Mean: 5.89umol/l
2 (45)        (4.4%)
Range: 32.7 – 35.7umol/l
Mean: 34.2umol/l
The levels that were considered normal for serum iron were 10-30 umol/l
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3.3 Transferrin Saturation
Decreased Increased
Peritoneal Dialysis 5 (22)          (22.7%)
Range:  11-19%
Mean: 16.4%
1 (22)          (4.5%)
54 %
Haemodialysis 2 (12)          (16.7%)
Range: 8 – 19%
Mean: 13.5%
6 (12)          (50%)
Range:  53 - 95 %
Mean: 71.67%
Non-dialysis 5 (11)          (27.3%)
Range: 7 – 19%
Mean:  14.4%
1 (11)          (9%)
61%
Total 12 (45)     (26.6%)
Range:  7 – 19%
Mean: 15%
8 (45)          (17.7%)
Range: 53-95%
Mean: 68.1%
The normal range for Transferrin saturation was 20-50%
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3.4 Ferritin Levels
Decreased Increased
Peritoneal Dialysis 0 (22)             (0.0%) 8 (22)       (36.4%)
Range: 449 – 1708ng/ml
Mean: 838.86ng/ml
Haemodialysis 0 (12)             (0.0%) 8 (12) (66.67%)
Range: 614 – 3076ng/ml
Mean: 1484.1ng/ml
Non-dialysis 1(11)              (9%)
29ng/ml
2 (11)              (18.1%)
Range: 509 – 590ng/ml
Mean: 549.5ng/ml
Total 1 (45)             (2.2%)
29ng/ml
18 (45)            (40%)
Range: 449 – 3076ng/ml
Mean:  1093.5ng/ml
The normal range for ferritin was 30-400ng/ml
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3.5 Vitamin C Levels
Deficient Toxic
Peritoneal Dialysis 8 (22) (22.7%)
Range: 5.7 – 17.8umol
Mean: 13.53umol
1 (22)          (4.5%)
45.2umol
Haemodialysis 5 (12)          (41.7%)
Range: 6.3 – 19.2umol
Mean: 13.14umol
0 (12)          (0%)          
Non-dialysis 5 (9)            (55.6%)
Range:  4 – 15.8umol
Mean: 10.9umol
1(9)             (11.1%)
71.6umol
Total 18 (43)        (41.8%)
Range: 4 – 19.2umol
Mean: 12.69umol
2 (43)          (4.6%)
Range: 45.2 – 71.6umol
Mean: 58.4umol
The normal range for Vitamin C levels was 20-40umol/WCC (44).
When looking at the results of the iron studies, more specifically iron levels, ferritin 
and transferrin saturation results, it is apparent that the non-dialysis group had the 
highest percentage of patients with biochemical iron deficiency.  However, when 
analysing the statistics for iron levels using the Fishers exact method it was clear that 
there was no statistical significance between the three groups (p value 0.605). 
When the Fishers exact test was performed for the transferrin saturation group the p-
value was 0.064 which was marginally significant. A p-value of less the 0.05 would 
have been considered truly significant.  There were two patients who biochemically 
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demonstrated iron toxicity; both these patients were on haemo-dialysis (4.4%). When 
analyzing the transferrin saturation results, 7 patients were considered to be iron toxic, 
again the haemodialysis group presenting with the highest number of patients. One of 
the factors contributing to this finding could have been the time of sampling of the 
bloods in relation to the timing of the intravenous iron which was unrecorded.
Studying the results showed that there are a number of patients who remain 
significantly anaemic despite adequate iron levels; this was not one of the aims or 
outcomes of the study but was merely an observation.  Further investigations would 
be needed to determine the cause of the anaemia.  
Analysis of the Vitamin C levels showed that a total of 41.8 % of patients (18 
candidates out of a total sample size of 43) assessed in this study were Vitamin C 
(ascorbic acid) deficient.  The highest percentage of patients who were deficient were
again noted to be in the non-dialysis group.  There was a relatively small sample size 
in this group which may have accounted for this (only 9 patients).  Analysing the 
statistics using the Fishers exact test showed no statistical significance between the 
three groups (p-value 0.435). Only two patients displayed Vitamin C toxicity, one in 
the peritoneal group and one in the non-dialysis group.  
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CHAPTER 4
DISCUSSION
Patients with chronic kidney disease have many complications; either as a result of 
the disease itself or as a result of the treatment which we initiate.   One of the most 
common abnormalities found in children suffering from chronic kidney disease is 
anaemia secondary to iron deficiency.  Iron toxicity is not common but does occur.   
It is well established that erythropoietin supplementation is essential in the failing 
kidney.  With this is the well documented fact that iron is required for erythropoietin 
to work effectively.  The dose of erythropoietin can also be significantly modified if 
iron deficiency is prevented.
In this study we showed that a significant percentage of children with chronic kidney 
disease (on haemodialysis, peritoneal dialysis or not yet dialysed but with established 
renal failure) are iron deficient.  All patients in this study were on iron 
supplementation when there haemoglobin levels dropped to within the anaemic range.
All patients on peritoneal dialysis or not yet dialysed who were anaemic were started 
on an oral iron formulation; all patients on haemodialysis were receiving intravenous 
iron.  
We need to explain the fact that between 20 and 26.6 percent of children in renal 
failure remained iron deficient despite iron supplementation. The best explanation for 
this is two-fold; non-compliance on treatment or inadequate dosing. The side-effects 
of oral iron include nausea, constipation, abdominal discomfort and tooth 
discolouration with the liquid forms. Uraemia also diminishes the intestinal 
31
absorption of iron even with severely diminished iron stores (45). This would not 
offer an explanation for the group on haemodialysis who are receiving intravenous 
iron while on the dialysis machine. We have also not taken into account functional 
iron deficiency.  This is characterized by the presence of adequate iron stores (normal 
ferritin levels), as defined by the K/DOQI guidelines, but an inability to sufficiently 
mobilise these stores when erythropoeisis is stimulated by an erythropoeitic agent.
Iron toxicity was also demonstrated in 4.4 % of the patients.  The two patients who 
demonstrated iron toxicity when analysing iron levels were both on haemodialysis.  
When looking at TSAT results, a higher percentage were toxic (15.5%); with two of 
the patients falling into this group on haemodialysis having extremely high ferritin 
levels (3076 and 1863).
A raised ferritin is also associated with chronic inflammation and therefore is not 
specific for iron metabolism (26); however, in view of a raised TSAT and iron level 
the raised ferritin results were probably significant in these two patients.  A group of 
patients in this study were noted to have raised ferritin levels despite normal or low 
iron and transferrin saturation levels; it is in this group that other causes of raised 
ferritin should be considered i.e. inflammation, infection or neoplasm (26). Infection 
with raised C - reactive protein levels was found to be the cause in certain individuals.
The analysis of the Vitamin C results revealed some interesting findings. Results
indicated that the group displaying the highest percentage of Vitamin C deficiency 
was in fact the non dialysis group (55.6%).  We did not specifically look at the overall 
nutrition of the patients enrolled in the study; particularly protein energy malnutrition.
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Poor nutrition may have in part explained the nutritional deficiencies evident in this 
particular group of patients. All patients enrolled in the study had their weight and 
height measured on the day the bloods were sampled.  Results indicate that 61 % of 
the girls had weight values which fell on or below the third centile (11 out of 18), 
while 74 % of the enrolled boys had weight on or below the third centile (20 out of 
27). When evaluating heights 76 % (13 out of 17) girls had measurements that fell on 
or below the third centile when comparing age equivalents.  When reviewing the male 
group 88.8 % of boys enrolled in the study had lengths recorded on or below the 3rd
centile when comparing with other boys their age.  It is clear from these findings that 
although no formal assessment of nutrition was analyzed on this group of patients, 
there is significant evidence to support malnutrition and poor growth. All patients in 
chronic renal failure are advised to be on a ‘renal diet’, with various restrictions.  Diet 
was not explored and considered in this study but clearly this would affect the 
Vitamin C and iron results.
There was no documented history of when patients received blood transfusions or had 
a confirmed infection (peritonitis; line sepsis) which would obviously affect their 
haemoglobin as well as their iron levels.  No patients in the study were on Vitamin C 
supplements; however, the ingestion of over the counter and other prescribed 
medications were not considered. Certain types of medications ingested may have 
influenced results; these include Proton Pump Inhibitors, ACE inhibitors and antacids.
Also, analysis of albumin levels in relation to Vitamin C levels would be interesting 
in particular in patients on peritoneal dialysis where this association has previously 
been documented (42). The differences in the levels of iron and Vitamin C were not 
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explored in the different ethnic groups due to the small sample size.  In future this 
area could be examined.
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CHAPTER 5
CONCLUSION
It was clear from this observational study that a significant number of patients with 
chronic renal insufficiency are Vitamin C and iron deficient.  Intravenous iron 
supplementation needs to be considered in the patients on peritoneal dialysis or in the 
group not yet dialysed who remain iron deficient despite oral iron supplementation. A 
further study could be the generated from this initial study; Vitamin C could be 
administered in therapeutic doses to children with chronic renal insufficiency while 
closely monitoring the levels.  Analysis of iron and haemoglobin should be repeated 
after Vitamin C has been administered to see whether there are any significant 
changes in these values. The volume of fluid exchanges and the percentage dextrose 
concentration used in patients on Peritoneal Dialysis may affect Vitamin C levels and 
this information should be documented in follow up studies. Also, if another study 
were undertaken, careful documentation of nutritional status, diet and albumin levels 
may reveal further useful information.
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APPENDICES
White Cell Vitamin C Assay
Modified from Marchand and Pelletier, International Journal Vitamin Nutrition 1977; 
47; pp. 236-247
CMC Solution:  0.9 grams NaCl
1 gram Methyl Cellulose
2 ml Glycerol
Make up to 100ml with distilled water
DNPH Solution:  2.2 % 2:4 dinitro-phenyl hydrazine in 10N H2SO4
DNPH Reagent Mixture:  20 volumes DNPH Solution
1 volume 5 % Thiourea
1 volume 0.6 % CuSO4.5H2O
Method:
Take 6 millilitres of EDTA blood which has been well mixed.
Add 0.6mls 1% CMC solution, mix well and allow to settle.
Take off 2 ml of plasma and place in a 15 ml conical plastic tube.  Fill up with normal 
saline to 12ml mark.  Mix Well.  Take off 0.5ml for a white cell count. 
Spin the rest for 10 minutes at approximately 2000rpm.  Decant the supernatant.
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Add 1.3ml 5% trichloracetic acid which breaks down the protein.  Make sure that the 
pellet is well in suspension (use an orange stick if necessary).  Spin for 10 minutes at 
2600rpm.
Take off 1ml supernatant and add 0.3ml of the DNPH reagent mixture to it.
Incubate for 4 hours at 37 degrees Celsius.
Place on ice and add 1.5mls 65% H2SO4.  Allow to stand for 30 minutes on ice.
Make a blank solution consisting of 1ml of 5% trichloracetic acid and 0.3mls of the 
DNPH reagent mixture.
Read at 520 nm, using blank as zero.
Standard Curve
Dilute 10g ascorbic acid in 1 litre of 5 % trichloracetic acid (TCA).  This is equivalent 
to 10mg/ml.
Dilute 1ml of the above solution in 100ml of 5 % trichloracetic acid (100ug/ml)
Make dilutions of this in 5% TCA as follows:
100ul in 1.0ml 5% TCA = 10ug/ml
200ul in 2.5ml 5% TCA = 8ug/ml
100ul in 2.0ml 5% TCA = 5ug/ml
100ul in 5.0ml 5% TCA = 2ug/ml
100ul in 10.0ml 5% TCA = 1ug/ml
100ul in 20.0ml 5% TCA = 0.5ug/ml
100ul in 50.0ml 5% TCA = 0.2ug/ml
3.  Incubate duplicate 1ml aliquots of each of the above solutions with 0.3ml of the 
DNPH reagent mixture for 4 hours as for the samples
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4.  Read at 520nm using a blank to zero as before.  Plot the OD against the 
concentration on normal graph paper.
Calculation
Calculate the concentration of the sample from the standard curve.
Concentration from standard curve (ug/ml) x 1.3 x 100 = ug Vitamin C x 10 
leucocytes
White cell count x 11.5
Normal Range:  20 – 40 ug/10 eight leucocytes
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CONSENT FOR PARTICIPATION IN IRON AND VITAMIN C 
STUDY
Dear Parent
My name is Tracey Lutz.  I am a paediatric registrar working in research in the renal 
unit (296) at Johannesburg Hospital, under the supervision of Dr Hahn. 
Your child has chronic renal failure and is attending our renal clinic.  One of the 
complications of chronic renal failure is anaemia and because of this your child is on 
erythropoietin (eprex) and iron supplementation (ferrous fumarate or venofer).
As part of my research I would like to analyze iron studies on all the patients with 
chronic renal failure. At the same time I would like to take an extra specimen of 
clotted blood (5mls / one teaspoon measure) to measure vitamin C levels; I would like 
to invite you to give permission for your child to volunteer to take part in the study.  
This will be done while your child’s routine monthly bloods are being taken, thereby 
not causing any unnecessary discomfort for your child.  Vitamin C is one of the 
water-soluble vitamins in our bodies that improves iron absorption. It has also been 
proven to improve the anaemia associated with renal failure when given with iron and 
erythropoeitin.  
The aim of my study is to see whether we are adequately supplementing iron in all our 
patients.  By looking at vitamin C levels we will determine whether our patients in 
chronic renal failure have subclinical (no signs to see on the patient) deficiency of this 
vitamin.
At the time of the study we would review your child’s file and would record some 
demographic details and information regarding the history of your child’s illness.  We 
will keep all information and results confidential.  At no point in time will your 
child’s information and blood results be made public knowledge.
Taking part in the study is voluntary and if you refuse your child’s care will not be 
affected in any way.  You can withdraw from the study at any time.  Feel free to 
contact me if you would like to ask more questions.
Thanking you
Tracey Lutz
Contact no.  488-3296   or LR bleep 22628
I  have read and understood the above information and 
agree that my child   ______________________ may participate in the study.
Signed  Date ________________________
Witness Place ________________________
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PATIENT CONSENT FOR PARTICIPATION IN IRON AND 
VITAMIN C STUDY
(Subjects over the age of 14 years)
Dear Patient
My name is Tracey Lutz.  I am a doctor working with children in the renal unit at 
Johannesburg Hospital, under the supervision of Dr Hahn.
You have chronic renal failure and are on certain medications as a result of that.  Two 
of the medications which you are taking are iron and erythropoietin (eprex). These 
treatments help prevent anaemia which can result in you feeling tired or dizzy. 
As part of my research I would like to analyze iron studies which are done on you as 
part of your routine monthly blood tests.  I would also like to take an extra 5mls (one 
teaspoon measure) of clotted blood to look at vitamin C levels; I would like to invite 
you to volunteer to take part in the study. Vitamin C may be low in your blood which 
may worsen your anaemia.  I would take this blood at the same time as your routine 
bloods to avoid any additional discomfort (pain) to you.
At the time of the study we would review your file and would record some details 
about you (e.g. your age, your gender etc.) and information regarding the history of 
your illness. We will keep all information and results confidential (secret), so that no 
person can see this information.
Taking part in the study is voluntary (you can choose whether you want to or not) and 
if you don’t want to take part your medical care will not be compromised.  You can 
withdraw from the study at any time.  Feel free to contact me if you would like to ask 
more questions.
Thanking you
Tracey Lutz
Contact no. 488-3296 or LR bleep 22628
I ________________________ have read and understood the above information and 
agree to take part in the study.
Signed __________________________             Date 
______________________________
Witness__________________________             
Place______________________________
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DATA COLLECTION SHEET
Analysis of iron studies and vitamin C levels in paediatric patients 
with chronic renal failure.
DEMOGRAPHIC DETAILS
STUDY CODE NUMBER:  _______________________________
AGE/DATE OF BIRTH:   _________________________
SEX: _________________________
HOSPITAL NUMBER:________________________
RACE:                  Black               White                           Coloured                               Asian
HISTORY
AETIOLOGY OF RENAL FAILURE:_________________________________
BIOPSY                                  YES                        NO
If Yes results:
DIALYSIS                 PERITONEAL             HAEMODIALYSIS             NONE  
DURATION OF DIALYSIS (years and months): _____________________________________
EXAMINATION
WEIGHT (KG): __________________               HEIGHT (CM):_________________________
BLOOD PRESSURE:_____________________________
GLOMERULAR FILTRATION RATE   (SCHWARTZ FORMULA):_______________________
INVESTIGATIONS
WCC
HAEMOGLOBIN
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MEAN CELL VOLUME
HAEMATOCRIT
IRON LEVELS
FERRITIN
TRANSFERRIN 
PERCENTAGE SATURATION (TSAT)
C-REACTIVE PROTEIN
VITAMIN C LEVELS
CURRENT  TREATMENT
ERYTHROPOEITIN      
TYPE AND DOSE 
ROUTE OF ADMINISTRATION
IRON
DOSE
ORAL OR INTRAVENOUS
42
43
REFERENCES
1.  Eschbach, J.W.  1989.  The anaemia of chronic renal failure:  Pathophysiology and 
the effects of recombinant erythropoietin.  Kidney International, volume 35; pp. 134-
148.
2.  Peco-Antic, A.  2003.  Anaemia management of children with chronic renal 
failure.  Bantao Journal 1 (2); pp. 65-66.
3. Priyadarshi, A., Shapiro, J.I.  2006. Erythropoeitin resistance in the treatment of 
the anemia of chronic renal failure.  Seminars in Dialysis, volume 19, number 4; pp.
273-278. 
4.  Krmar, I.T., Gretz, N., Klare, B., Wuhl, E. et al.  1997.  Renal function in 
predialysis children with chronic renal failure treated with erythropoietin.  Paediatric 
Nephrology, volume 11; pp. 69-73.
5. Rigden, S.P., Montine, G., Morris, M., Kenneth, G. et al. 1990.  Recombinant 
human erythropoietin therapy in children maintained by haemodialysis.  Paediatric 
Nephrology, volume 4; pp. 618-622.
6.  Strippoli, G.F., Craig, J.C., Manno, C., Francesco, P. et al.  2004.  Haemoglobin 
targets for the anaemia of chronic kidney disease:  a meta-analysis of randomized, 
controlled trials.  Journal of the American Society of Nephrology, volume 15, number 
12; pp 3154-3165.
44
7.  Pendse, S., Singh, A.K.  2005.  Complications of chronic kidney disease:  
Anaemia, mineral metabolism and cardiovascular disease.  Medical Clinics of North 
America, volume 89, number 3; pp 549-561.
8.  Morgan, H.E., Gautam, M., Geary, D.F.  2001.  Maintenance intravenous iron 
therapy in paediatric haemodialysis patients.  Paediatric Nephrology, volume 16; pp. 
779-783.
9.  Littlewood, T.J.  2008.  Normalization of Haemoglobin in Patients with CKD may 
cause harm:  But what is the mechanism.  American Journal of Kidney Diseases, 
volume 52, issue 4; pp 727-731.
10. Gillespie, R.S. and Wolf, F.M.  2004.  Intravenous iron therapy in paediatric 
haemodialysis patients: a meta-analysis.  Paediatric Nephrology, volume 19; pp. 662-
666.
11. Van Wyck, D.B., Stivelman, J.C., Ruiz, J., Kirlin, L. et al.  1989.  Iron status in 
patients receiving erythropoietin for dialysis-associated anaemia.  Kidney 
International, volume 35; pp. 712-716.
12. Van Damme-Lombaerts, R., Broyer, M., Businger, J., Baldauf, C. et al.  1994.  A 
study of recombinant human erythropoietin in the treatment of anaemia of chronic 
renal failure in children on haemodialysis.  Paediatric Nephrology, volume 8; pp. 338-
342.
45
13.   Rossert, J., Fouqueray, B., Boffa, J.J.  2003.  Anaemia management and the 
delay of chronic renal failure progression.  Journal of the American Society of 
Nephrology, volume 14, number 7; pp 5173 -5177.
14. Schroder, C.  2003.  The management of anaemia in paediatric peritoneal dialysis 
patients.  Paediatric Nephrology, volume 18; pp. 805-809.
15. Macdougall, I.C.  2002.  Darbepoetin alfa:  A new therapeutic agent for renal 
anaemia.  Kidney International, volume 61, supplement 80; pp.S55- S61.
16. Nakagawa, T.  Darbepoetin alpha is highly cost-effective compared with Epoetin 
alpha in the treatment of renal anaemia; a brief report from a haemodialysis clinic in 
Japan. 2008.  Therapeutic Apheresis and Dialysis, volume 12, issue 6; pp 531-532.
17. Kalantar-Zadeh, K., Lee, G., Miller, J, Streja, E. et al.  2009. Predictors of 
hyporesponsiveness to Erythropoeisis Stimulating Agents in Haemodialysis Patients.  
American Journal of Kidney Diseases, volume 53, issue 5; pp 823-834.
18. Warady, B.A., Kausz, A., Lerner, G., Brewer, E. et al.  2004.  Iron therapy in the 
paediatric haemodialysis population.  Paediatric Nephrology, volume 19; pp 655-661.
19.  Markowitz, G.S., Kahn, G.A., Feingold, R.E., Coco, M. et al.  1997.  An 
evaluation of the effectiveness of oral iron therapy in haemodialysis patients receiving 
46
recombinant human erythropoietin.  Clinical nephrology, volume 48, number 1; pp. 
34-40.
20.  Aronoff, G.R., Bennett, W.M., Blumenthal, S., Charytan,. et al.  2004.  Iron 
sucrose in haemodialysis patients:  Safety of replacement and maintenance regimens.  
Kidney International, volume 66; pp. 1193-1198.
21.  Kalantar-Zadeh, K., McAllister, C.J., Lehn, R.S, Liu, E. et al.  2004.  A low 
serum iron level is a predictor of poor outcome in haemodialysis patients.  American 
Journal of Kidney Diseases, volume 43, number 4; pp 671-684.
22.  NKF-K/DOQI Clinical Practice Guidelines.  2000.  American Journal of Kidney 
Disease 2001, volume 37 supp 1.
23.  Tsuchiya, K., Saito, M., Okano-Sugiyama, H., Nihei, H. et al.  2005.  Monitoring 
the content of reticulocyte haemoglobin as the progression of anaemia in nondialysis 
chronic renal failure patients.  Renal Failure, volume 27; pp. 59-65.
24.  Kim, J.M., Ihm, C.H., Kim, H.J.  2006.  Evaluation of reticulocyte haemoglobin 
content as marker of iron deficiency and predictor of response to intravenous iron in 
haemodialysis patients.  International Journal Laboratory Haematology 2008, 30 pp 
46-52.
47
25.  Brugnara, C., Schiller, B., Moran, J.  2006. Reticulocyte Haemoglobin 
equivalent (Ret HE) and assessment of iron-deficient states.  Clinical Lab 
Haematology, volume 28 (5); pp 303-308.
26.  Canavese, C., Bergamo, D., Ciccone, G., Longo, F. et al. 2004.  Validation of 
serum ferritin values by magnetic susceptometry in predicting iron overload in 
dialysis patients.  Kidney International volume 65; pp. 1091-1098.
27.  Macdougall, I.C., Tucker, B., Thompson, J., Tomson, C. et al.  1996.  A 
randomized controlled study of iron supplementation in patients treated with 
erythropoietin.  Kidney International, volume 50; pp.1 1694-1699.
28.  Eleftheriadis, T., Liakopoulos, V., Antoniadi, G., Kartsios, C. et al. 2009.  The 
role of Hepcidin in iron haemostasis and anaemia in haemodialysis patients.  
Seminars in Dialysis, volume 22, number 1; pp 70-77.
29. Auerbach, M., Goodnough, L.T., Picard, D., Maniatis, A.  2007.  The role of 
intravenous iron in anaemia management and transfusion avoidance.  Transfusion 
2008, volume 48; pp 988 -1000.
30.  Ganz T. 2003. Hepcidin, a key regulator of iron metabolism and mediator of 
anaemia of inflammation. Blood, volume 102; pp 783-788.
48
31. Tsuchihashi, D., Takaya, A., Komaba, H, Fujii, H. et al.  2007.  Serum Pro-
hepcidin as an indicator of iron status in dialysis patients. Therapeutic Apheresis and 
Dialysis 2008, volume 12(3); pp. 226-231.
32.  Kulaksiz H., Gehrke S., Janetzko A., Rost, D. et al.  2004.  Pro-hepcidin:  
expression and cell specific localisation in the liver and its regulation in hereditary 
haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut, volume 53; 
pp 735-743.
33.  Fishbane, S. 2003.  Safety in iron management.  American Journal of Kidney 
Diseases, volume 41, number 5; pp 18-26.
34.  Fishbane, S.  2007.  Iron Management in Non dialysis-Dependent Chronic 
Kidney Disease.  The American Journal of Kidney Diseases, volume 49, Issue 6; pp 
736-745.
35.  St. Peter, W.L., Obrador, G.T., Roberts, T.L, Collins, A. et al.  2005.  Trends in 
intravenous iron use among dialysis patients in the United States (1994-2002).  
American Journal of Kidney Diseases, volume 46, number 4; pp 650-660.
36.  Agarwal, R. 2004.  Transferrin saturation with intravenous irons:  An in vitro 
study.  Kidney International, volume 66; pp. 1139-1144.
49
37.  Ruiz-Jaramillo, M., Guizar-Mendoza, J.M., Guitierrez-Navarro, M., Dubey-
Ortega, L. et al.  2004.  Intermittent versus maintenance iron therapy in children on 
haemodialysis: a randomized study.  Paediatric Nephrology, volume 19; pp. 77-81.
38. Coyne, D.  2008.  A Comprehensive Vision for Intravenous Iron Therapy.  
American Journal of Kidney Diseases, volume 52, Issue 6; pp 514-520.
39.  Rozen-Zvi, B., Gafter-Gvili, A., Paul, M., Leibovici, L. et al 2008.  Intravenous 
versus Oral Iron Supplementation for the Treatment of Anaemia in CKD:  Systematic 
Review and Meta-analysis.  American Journal of Kidney Disease, volume 52, issue 5; 
pp 897-906
40. Deicher, R., Horl, W. 2003.  Vitamin C in chronic kidney disease and 
haemodialysis patients.  Kidney Blood Pressure Res, volume 26 ; pp. 100-106.
41.  Canavese, C., Petrarulo, M., Massarenti P., Berutti, S. et al.  2005.  Long term, 
low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in 
haemodialysis patients.  American Journal of Kidney Diseases, volume 45, number 3; 
pp. 540-549.
42.  Singer, R., Rhodes, H.C., Chin, G., Kulkarni, H. et al. 2007.  High prevalence of 
ascorbate deficiency in an Australian peritoneal dialysis population.  Nephrology 
2008, volume 13; pp. 17-22.
50
43.  Chen, W., Lin, Y., Yu, F., Kao, W. et al.  2003.  Effect of ascorbic acid 
administration in haemodialysis patients on in vitro oxidative stress parameters:  
Influence of serum ferritin levels.  American Journal of Kidney Diseases, volume 42, 
number 1.
44. Attwood, E., Robey, E., Ross, J., Bradley, F. et al. 1974. Determination of platelet 
and leucocyte Vitamin C and iron levels found in normal subjects.  Clinical Chimica 
Acta, volume 54, issue 1; pp 95-105.
45.  Tenbrock, K., Muller-Berhaus, J., Michalk, D., Querfeld, U. et al.  1999.  
Intravenous iron treatment of renal anaemia in children on haemodialysis.  Paediatric 
Nephrology, volume 13; pp. 580-582.
51
Additional Reading Material
Adamson, J.W. and Eschbach, J.W. 1998. Erythropoeitin for end-stage renal disease.  
The New England Journal of Medicine. Boston:  Aug 27, Volume 339, Issue 9; pp 
625-628.
Besarab, A., Reyes, C.M., Hornberger, J.  2002. Meta-Analysis of subcutaneous 
versus intravenous epoetin in maintenance treatment of anaemia in haemodialysis 
patients.  American Journal of Kidney Diseases, volume 40, no 3; pp. 439-446.
Burke, J.R.  1995.  Low-dose subcutaneous recombinant erythropoietin in children 
with chronic renal failure. Paediatric Nephrology, volume 9; pp. 558-561.
Coyne, D. 2008. Introduction to “A Road Map for Intravenous Iron and Anaemia 
Management: Preparing for the Future”.  American Journal of Kidney Diseases, 
volume 52, Issue 6 Supplement; pp 51-54.
Fitzimons, E. and Brock, J.H. 2001. The anaemia of chronic disease.  BMJ.  
322(7290); pp. 811-812.
Goodnough, L.T., Skikne, B., and Brugnara, C. 2000.  Erythropoeitin, iron, and 
erythropoiesis.  Blood, volume 96, number 3; pp. 823-833.
Himmelfarb, J.  2005.  Haemodialysis complications.  American Journal of Kidney 
Diseases, volume 45, number 6; pp 1122-1131.
52
Horl, W.  2007.  Iron therapy for renal anaemia: how much needed, how much 
harmful?  Paediatric Nephrology, volume 22 (4); pp 480-489.
Jelkmann, W.  2007.  Erythropoeitin after a century of research:  younger than ever.  
European Journal of Haematology, volume 78; pp 183-205.
Kapoian, T. 2008.  Challenge of Effectively Using Erythropoeisis-Stimulating Agents 
and Intravenous Iron. American Journal of Kidney Diseases, volume 52, issue 6, 
supplement; pp 521-528.
Kaufman, J.S., Reda, D.J., Fye, C.L., Goldfarb, D. et al. 1998. Subcutaneous 
compared with intravenous epoetin in patients receiving haemodialysis.  The New 
England Journal of Medicine, volume 339, issue 9; pp. 578-583.
Kaufman, J.S., Reda, D.J., Fye, C.L, Goldfarb, D. et al. 2001.  Diagnostic value of 
iron indices in haemodialysis patients receiving epoetin.  Kidney International, 
volume 50; pp. 300-308.
Mak, R.H.  1998.  Metabolic effects of erythropoietin in patients on peritoneal 
dialysis.  Paediatric Nephrology, volume 12; pp 660-665.
Mydlik, M. Derzsiova, K. Boldizsar J., Hribikova, M. et al.  2003.  Oral use of iron 
with vitamin C in haemodialysed patients.  Journal of Renal Nutrition, volume 13; pp 
47-51.
53
Pecoits-Filho, R., Sylvestre, L.C., Stenvinkel, P.  2005.  Chronic kidney disease and 
inflammation in paediatric patients:  from bench to playground.  Paediatric 
Nephrology, volume 20; pp. 714-720.
Tarng, D., Chen, T.W., Huang, T. 1995.  Iron metabolism indices for the prediction of 
the response and resistance to erythropoietin therapy in maintenance haemodialysis 
patients.  American Journal of Nephrology, volume 15; pp. 230-237.
Toblli, J., Cao, G., Rivas, C., Kulaksiz, H. et al.  2008.  Heart and iron deficiency 
anaemia in rats with renal insufficiency:  The role of hepcidin.  Nephrology, volume 
13; pp 636-645.
Warady, B.A., Zobrist, R.H., Wu, J., Finan, E. et al. 2005  Sodium ferric gluconate 
complex therapy in anaemic children on haemodialysis.  Paediatric Nephrology, 
volume 20; pp. 1320-1327.
Wazny, L., Stojimirovic, B.B., Heidenheim, P., Blake, P. et al.  2002.  Factors 
influencing erythropoietin compliance in peritoneal dialysis patients.  American 
journal of kidney diseases, volume 40, number 3; pp. 623-628.
